Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks Announces Participation in Upcoming Investor Conference
07:30am, Wednesday, 21'st Dec 2022
VANCOUVER, British Columbia--( BUSINESS WIRE )--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management
Why Zymeworks Inc. (ZYME) Might be Well Poised for a Surge
01:32pm, Thursday, 24'th Nov 2022
Zymeworks Inc. (ZYME) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zymeworks Announces Participation in Upcoming Investor Conference
08:30am, Tuesday, 22'nd Nov 2022
VANCOUVER, British Columbia--( BUSINESS WIRE )--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
10:45pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 23.40% and 44.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Q3 2022 Earnings Call Transcript
08:24pm, Tuesday, 08'th Nov 2022
Zymeworks Inc. (NYSE:ZYME ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Neil Klompas - President & COO Kenneth Galbraith -
Relentless Zymeworks stock eyes a breakout from channel. Buyers should keep watch
02:12pm, Friday, 04'th Nov 2022
Zymeworks Inc. (NYSE:ZYME) could be one of the best biotech stocks to buy in November. The stock, which has crashed by 55.71% year-to-date, trades within narrow ranges, but the upside potential is gro
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket
11:58am, Wednesday, 02'nd Nov 2022 Benzinga
Gainers
Avinger, Inc. (NASDAQ: AVGR) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022.
Arcturus Thera
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
Why Shares of Zymeworks Rose 12.18% on Monday
08:42pm, Monday, 31'st Oct 2022 The Motley Fool
The biotech stock's shares may have been pushed by a short squeeze.
Why Shares of Zymeworks Rose 12.18% on Monday
04:42pm, Monday, 31'st Oct 2022
The biotech stock's shares may have been pushed by a short squeeze.
Jazz Pharmaceuticals' Deal With Zymeworks Offers Good Reward-Risk Ratio
09:02am, Wednesday, 26'th Oct 2022
Jazz Pharmaceuticals will pay $50 million upfront for an option to in-license Zymeworks' zanidatamab. Zymeworks carries most of the risk until Jazz opts in. If the deal goes through, Zymeworks would b
Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
04:38am, Wednesday, 26'th Oct 2022
Zymework's Jazz deal will bring $325mn in milestone payment if zanidatamab's BTC data is good. BTC data comes out by end 2022.
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
05:35pm, Friday, 21'st Oct 2022 Benzinga
SVB Leerink downgraded Zymeworks Inc (NASDAQ: ZYME) to Market Perform with a price target of $8, down from $19 following the recent divestiture of zanidatamab to Jazz Pharmaceuticals plc (NASDA
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
02:11pm, Friday, 21'st Oct 2022 Benzinga
Upgrades
SVB Leerink upgraded the previous rating for Moderna Inc (NASDAQ:MRNA) from Underperform to Market Perform. Moderna earned $5.24 in the second quarter, compared to $6.46 in the year-ago quart
Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals
05:36pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.
